• ReNerve gains marketing approval in Bahrain, its first approval in the Middle East
• Partnership with Union MediScience to commercialize the NervAlign® Nerve Cuff™ product in Bahrain
• The Middle East and North Africa market is worth over USD$80M per annum and growing at 35%

ReNerve Limited (ASX:RNV), a pioneering medical device company transforming peripheral nerve repair, has announced that it has received marketing approval in Bahrain. This approval comes as a result of ReNerve having worked with its partner in the region, Union MediScience B.S.C ('Union MediScience'). The two companies will now work to commercialize the NervAlign® Nerve Cuff™ product in Bahrain, and utilize information generated from early cases to expand further regional approvals. The Middle East region, as a market opportunity, poses strong growth potential alongside other key markets as awareness and demand for nerve repair and replacement steadily increases. Market reports suggest the total Middle East and North Africa (MENA) market is worth over USD$80M per annum and growing at over 35%. The partnership with Union MediScience, announced in December 2024, granted them the rights to market and sell ReNerve's flagship product, the NervAlign® Nerve Cuff, across five key Middle Eastern countries: Bahrain, Saudi Arabia, Kuwait, the United Arab Emirates (UAE), and Qatar. Union MediScience is a leading company in the Middle East that represents well-known manufacturers worldwide through the supply of medical equipment, medical goods and medicines.

ReNerve achieved 38% revenue growth in FY24, reaching $177k in sales. The global nerve repair biomaterials market was valued at USD$1.96 billion in 2024 and is projected to grow at a CAGR of 17.8% from 2024 to 2031 to USD$6.19 billion.